Asad Haider
Stock Analyst at Goldman Sachs
(1.69)
# 3,155
Out of 4,810 analysts
5
Total ratings
50%
Success rate
0.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $154.36 | +11.43% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $754.35 | +17.72% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $179.10 | +8.32% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $51.34 | +7.13% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $22.12 | +13.02% | 1 | Apr 8, 2025 |
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $154.36
Upside: +11.43%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $754.35
Upside: +17.72%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $179.10
Upside: +8.32%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $51.34
Upside: +7.13%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $22.12
Upside: +13.02%